Johnson & Johnson (JNJ) Stock Forecast & Price Target

Johnson & Johnson
Bull Case

Here are some ways that investors could benefit from investing in Johnson & Johnson:

• Johnson & Johnson recently demonstrated significant clinical success in its oncology franchise, with new data showing that a single infusion of CARVYKTI delivered five-year treatment-free remissions in 50% of patients with early-line relapsed or refractory multiple myeloma, supporting the long-term growth potential of its cancer therapies.
• The company's neuroscience portfolio is expanding rapidly following the acquisition of Intra-Cellular Therapies, as CAPLYTA delivered statistically significant and rapid symptom improvement in a Phase 3 study for bipolar I mania, potentially broadening its revenue base beyond schizophrenia and bipolar depression.
• Johnson & Johnson is strengthening its immunology pipeline with the FDA approval of ICOTYDE for moderate-to-severe plaque psoriasis and positive Phase 4 results for TREMFYA in axial psoriatic arthritis, providing a potential successor to declining STELARA sales and addressing a high-growth therapeutic area.
• With a current stock price of $272.16, the company offers a defensive dividend yield of 1.98% and a low beta of 0.24, making it an attractive option for income-focused investors seeking stability and lower volatility compared to the broader market.
• Analysts maintain a consensus rating of Moderate Buy with a price target of $274.13, reflecting confidence in the company's ability to execute its strategy, as evidenced by recent upgrades from firms like Freedom Capital and Citigroup which raised their targets based on strong earnings beats and guidance.